In a recent study, Maciocia et al. develop a novel T cell receptor beta (TCRB) constant C1-chain-directed cellular immunotherapy for the treatment of T cell malignancies.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Pishko, A. & Nasta, S.D. Transl. Cancer Res. 6, 93–103 (2017).
Ramos, C.A. et al. J. Clin. Invest. 126, 2588–2596 (2016).
Toyonaga, B., Yoshikai, Y., Vadasz, V., Chin, B. & Mak, T.W. Proc. Natl. Acad. Sci. USA 82, 8624–8628 (1985).
Schwartz, R.H. Annu. Rev. Immunol. 3, 237–261 (1985).
Warner, K. et al. Curr. Hematol. Malig. Rep. 8, 163–172 (2013).
Nikolich-Zugich, J., Slifka, M.K. & Messaoudi, I. Nat. Rev. Immunol. 4, 123–132 (2004).
The authors declare no competing financial interests.
About this article
Cite this article
Palomero, T., Ferrando, A. Targeted cellular immunotherapy for T cell malignancies. Nat Med 23, 1402–1403 (2017). https://doi.org/10.1038/nm.4458
This article is cited by
Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products
Pharmaceutical Research (2021)
Pregnant rats exposed to low-level methylmercury exhibit cerebellar synaptic and neuritic remodeling during the perinatal period
Archives of Toxicology (2020)